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Abstract: Papillary thyroid carcinoma (PTC) variants exhibit different prognosis, but critical
characteristics of PTC variants that contribute to differences in pathogenesis are not well-known. This
study aims to characterize dysregulated immune-associated and cancer-associated genes in three
PTC subtypes to explore how the interplay between cancer and immune processes causes differential
prognosis. RNA-sequencing data from The Cancer Genome Atlas (TCGA) were used to identify
dysregulated genes in each variant. The dysregulation profiles of the subtypes were compared using
functional pathways clustering and correlations to relevant clinical variables, genomic alterations,
and microRNA regulation. We discovered that the dysregulation profiles of classical PTC (CPTC) and
the tall cell variant (TCPTC) are similar and are distinct from that of the follicular variant (FVPTC).
However, unique cancer or immune-associated genes are associated with clinical variables for each
subtype. Cancer-related genes MUC1, FN1, and S100-family members were the most clinically
relevant in CPTC, while APLN and IL16, both immune-related, were clinically relevant in FVPTC.
RAET-family members, also immune-related, were clinically relevant in TCPTC. Collectively, our data
suggest that dysregulation of both cancer and immune associated genes defines the gene expression
landscapes of PTC variants, but different cancer or immune related genes may drive the phenotype of
each variant.
Keywords: papillary thyroid carcinoma; cancer immunology; microRNA
1. Introduction
Thyroid carcinoma is currently the fastest growing cancer in the world and is the most common
endocrine carcinoma in the Western world [1]. The yearly occurrence of thyroid cancer has more
than doubled in the past two decades, with most of this growth being attributed to papillary thyroid
carcinoma (PTC), which constitutes over 80% of all thyroid cancer cases [1]. Papillary thyroid carcinoma
cases are divided into subtypes differentiated by physiology and clinical outcomes. The three most
common subtypes consist of classical (CPTC), follicular-variant (FVPTC), and tall cell (TCPTC) PTC,
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with CPTC being the most common subtype and TCPTC being the least common subtype. Clinical
outcomes vary between these subtypes. Most notably, TCPTC is characterized by higher rates of
mortality, tumor recurrence, distant metastasis, and lymph node metastasis than the other subtypes [2].
FVPTC is much more benign, as it has been correlated with much lower mortality and metastasis
rates than CPTC and TCPTC [2]. A recent study of FVPTC has resulted in further sub-classification
of this phenotype into the invasive (iFVPTC) and noninvasive (niFVPTC), also called encapsulated,
sub-variants [3]. niFVPTC has been reclassified as noninvasive follicular thyroid neoplasm with
papillary-like nuclear features (NIFTP) because it resembles benign tumors more than carcinomas [4,5].
However, this classification is largely based on pathological tumor features, with little known about
the genotypic differences between the sub-variants.
Despite increases in thyroid cancer cases, few mechanisms that differentiate between PTC subtype
pathogenesis and prognosis have been identified. The most prominent mechanism studied is the point
mutation of the BRAF proto-oncogene, which results in the expression of the BRAF-V600E mutant
protein. This protein promotes tumorigenesis by activating the mitogen-activated protein kinase
(MAPK) signaling pathway [6]—a pathway crucial for cell proliferation and survival. This mutation
has been shown to be present predominantly in CPTC and TCPTC patients and is correlated with an
aggressive phenotype contrary to the slow-growing nature of PTC in general. Additionally, the mutant
BRAF protein may have synergistic effects with other mutations, namely through the newly identified
relationship it has with telomerase reverse transcriptase (TERT) promoter mutations [7]. It has been
demonstrated that clinical prognosis is significantly worse when the BRAF mutation is present along
with a TERT mutation, complicating the role that BRAF has in thyroid cancer [7].
The second most prevalent mutation is on RAS and its isoforms, HRAS, NRAS, and KRAS. These
mutations are dual activators of the MAPK and the phosphatidylinositol 3-kinase/Akt (PI3K/AKT)
pathways, but more commonly activate the latter pathway in promoting tumorigenesis in FVPTC
patients [8].
Treatment of thyroid cancer has high success rates, with relatively low tumor recurrence. Currently,
the most common treatments include surgery and radioactive iodine therapy, and to a lesser extent,
chemotherapy, external beam radiation, and targeted therapy [9]. However, the aforementioned
treatments come with their own problems despite their efficacy. Thyroidectomy is limited to
non-metastatic tumors and carries with it the inherent risks of surgery. Radioactive iodine therapy,
although effective for most non-invasive tumors, has varying effectiveness when applied to PTC,
as thyroid tumors are able to develop a resistance to the uptake of iodine. This is caused by the
mutant BRAF-V600E protein, which mediates the silencing of the sodium/iodine symporter via the
up-regulation of certain epigenetic pathways [10], thereby rendering radioactive iodine ineffective
from a treatment standpoint. Although chemotherapy is the most widespread and effective option
for eradicating late-stage carcinomas, its accompanying morbidity is well documented. The current
most prevalent targeted therapy approved by the FDA for thyroid cancer is the administration of the
BRAF inhibitor dabrafenib combined with the MAPK inhibitor trametinib [11]. Although promising
in theory, this combination is only effective for carcinomas that test positive for the BRAF mutation,
which is not necessarily present in all CPTC or TCPTC tumors. Furthermore, in studies conducted on
thyroid cancer patients who had the BRAF mutation, it was found that only 4% of patients experienced
a complete response when exposed to this new therapy regimen [12].
Because of the drawbacks and varying patient responses to current cancer modalities,
the application of immunotherapy may also be a promising alternative option. Potential
immunotherapies have revolved around exploiting checkpoint inhibitors involved in immune pathways
associated with cancer progression, best exemplified by recent findings identifying the usage of
checkpoint inhibitors and CAR-T as an effective way to increase drug effectiveness in patients [13,14].
In previous studies by our lab, thyroid cancer was identified as one of the most immunogenic cancers,
suggesting potential for effective immune therapies in PTC treatment (Li et al, paper submitted for
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publication). However, there are few conclusive studies that identify novel targets for immunotherapy
within the genome and transcriptome.
In this study, we analyzed the co-dysregulation of immune-associated (IA) and cancer-associated
(CA) genes in the different subtypes of PTC using a multi-scale approach, using data provided
by The Cancer Genome Atlas (TCGA). We first identified gene dysregulation on the scale of RNA
expression. We then examined these dysregulations for significance on the scales of clinical variables
correlations, copy number variation/aneuploidy correlations, mutation correlations, and micro-RNA
regulation to identify key IA and CA genes that differentiate PTC subtypes from each other. In addition,
on a pathways scale, we clustered IA and CA genes based on function to determine coordinated
dysregulations of biological processes that define each PTC subtype.
2. Results
2.1. Similarities and differences between gene dysregulation landscapes of PTC subtypes
RNA-sequencing data from The Cancer Genome Atlas (TCGA) for four sample cohorts, one of
each PTC subtype and one of solid tissue normal samples, were downloaded. Sequencing data were
used to identify significantly dysregulated genes between groups in each cohort by utilizing differential
expression analysis (FDR <0.05, Figure 1A, Tables S1–S6). The genes were then filtered using a list
of known IA and CA genes, so only genes implicated in immune or cancer-related processes were
retained as candidates for further analyses. The lists of dysregulated genes from each cohort were
compared to identify similarities and differences between cohorts (Figure 1B).
Cancers 2019, 11, x 3 of 18 
 
In this study, we analyzed the co-dysregulation of immune-associated (IA) and cancer-
associated (CA) genes in the different subtypes of PTC using a multi-scale approach, using data 
provided by The Cancer Genome Atlas (TCGA). We first identified gene dysregulation on the scale 
of RNA expression. We then examined these dysregulations for significance on the scales of clinical 
variables correlations, copy number variation/aneuploidy correlations, mutation correlations, and 
micro-RNA regulation to identify key IA and CA genes that differentiate PTC subtypes from each 
other. In addition, on a pathways scale, we clustered IA and CA genes based on function to determine 
coordinated dysregulations of biological processes that define each PTC subtype. 
. s lts 
   D ff  t e  Gene Dysregulation Landscapes of PTC Subtypes 
              
      li  i  l l ,  l .    
 to identify significantl  dysregulat d genes between groups in each cohort by utilizing 
differential expres ion analysis (FDR <0.05, Figure 1A, Tabl  S1–Table S6). The genes were then 
filtered using  list of known IA a d CA genes, so only genes implicated in immun  or cancer-related 
processes were ret ined as candidates for further analyses. The lists of dysregulated genes fr m each 
hort were compared to identify similarities and diff rences between cohorts (Figures 1B). 
 
Figure 1. Study overview and differential expression analysis. (A) Schematic of analyses and 
workflow. (B) Venn diagram illustrating the unique and common significantly dysregulated IA genes 
after differential expression analysis of samples from each type vs. normal samples. Volcano plots 
depict statistical significance and fold change of differential expression analyses for all CA and IA 
genes. Red datapoints represent genes with expression that correlates with MACIS score. (C) 
Schematic of dysregulated genes that characterize each PTC subtype. Both differential expression 
results and clinical variable correlations results were used to determine the most important genes to 
each subtype. Gene names labeled in blue represent downregulation in a subtype and red represents 
upregulation in a subtype. 
A total of 153 genes were significantly dysregulated in all three subtypes when compared to 
normal samples (Figures 1B). 207 genes were dysregulated in both CPTC and TCPTC, 18 genes were 
dysregulated in both FVPTC and CPTC, and 20 genes are dysregulated in both FVPTC and TCPTC. 
This suggests that the landscape of IA and CA dysregulation is most similar between TCPTC and 
Figure 1. Study overview and differential expression analysis. (A) Schematic of analyses and workflow.
(B) Venn diagram illustrating the unique and common significantly dysregulated IA genes after
differential expression analysis of samples from each type vs. normal samples. Volcano plots depict
statistical significance and fold change of differential expression analyses for all CA and IA genes.
Red datapoints represent genes with expression that correlates with MACIS score. (C) Schematic
of dysregulated genes that characterize each PTC subtype. Both differential expression results and
clinical variable correlations results were used to determine the most important genes to each subtype.
Gene names labeled in blue represent downregulation in a subtype and red represents upregulation in
a subtype.
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A total of 153 genes were significantly dysregulated in all three subtypes when compared to
normal samples (Figure 1B). 207 genes were dysregulated in both CPTC and TCPTC, 18 genes were
dysregulated in both FVPTC and CPTC, and 20 genes are dysregulated in both FVPTC and TCPTC.
This suggests that the landscape of IA and CA dysregulation is most similar between TCPTC and
CPTC. Interestingly, 300 genes were dysregulated solely in TCPTC, while only 22 were dysregulated
solely in CPTC, suggesting that while TCPTC is most similar to CPTC in gene dysregulation, it is
still relatively distinct compared to the other subtypes. A larger number of genes are dysregulated in
TCPTC than in other subtypes.
From volcano plots of differential expression results, we observe that the fold changes of most
dysregulated genes in FVPTC were not significant (|logFC| > 1), whereas the fold changes of IA and
CA genes are much higher in the other two subtypes (Figure 1B). These results suggest that FVPTC
and normal tissue are relatively similar, and the lack of high fold-change dysregulation may explain
the relatively benign phenotype of FVPTC.
Due to the important differences between the newly classified variants of FVPTC, we attempted
to investigate immune-associated elements that may differ between them. TCGA data was limited in
this regard as FVPTC patients were not further classified into subtypes. We looked to sequencing data
from a previous study, Pool et al. [15], and performed differential expression analysis on niFVPTC vs
iFVPTC samples (Figure S1). The genotypes of both sub-variants were similar, as evidenced by the
small number of differentially expressed genes. Only a limited number of IA genes were found to be
significantly dysregulated between the two sub-variants. We therefore found that the determining
factor of FVPTC morphology may not be related to immune-associated elements.
Using differential expression data, clinical variable correlations, genomic alteration correlations,
and pathways associations, we have compiled a list of genes most implicated in each PTC subtype
and that critically define the molecular difference between the subtypes (Figure 1C). Our most salient
findings will be presented in the sections below.
2.2. Filtering differentially expressed genes by MACIS score
Due to the low patient mortality rate that is characteristic of thyroid cancer in general, differentially
expressed genes were further filtered by patient prognosis using the MACIS scoring system. After
MACIS scores were divided into four categories, the Kruskal-Wallis test was used to analyze a trend in
potential patient mortality that corresponds with a direction of gene dysregulation (p < 0.05). Genes
exhibiting a significant correlation were denoted on the volcano plots (Figure 1B). We note that most of
the genes with high statistical significance of differential expression (y-axis on volcano plots) exhibited
correlation with MACIS score in the TCPTC vs. normal tissue comparison, which may indicate their
ability to confer the more aggressive phenotype of TCPTC. Only MACIS-score correlated genes were
candidates for further analysis.
2.3. MUC1, FN1, S100 family genes, and CA/IA pathways define the CPTC dysregulation landscape
The Cytoscape ReactomeFIViz plugin [16] allowed us to create functional clusters of dysregulated
genes, with the purpose of grouping genes based on similarity of function in relation to biological
pathways. Both CA and IA pathways are strongly implicated in the dysregulation landscape of CPTC,
with the largest cluster of genes being linked to both the IA pathway of Fc-epsilon receptor signaling
and the CA pathways of p53 effectors and Ap-1 transcription factor network (Figure 2A). CA pathways
of PI3K-Akt signaling, MAP kinase cascade, TGF-beta signaling, and retinoic acid signaling account
for the next two largest functional clusters, while IA pathways of lymphocyte signaling and cytokine
signaling account for the subsequent three largest functional clusters.
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Figure 2. Pathways and genes characterizing the CPTC dysregulation landscape. (A) ReactomeFIViz
functional clustering analysis for dysregulated genes in CPTC vs normal samples. CA or IA gene nodes
are distinguished by black text and red or blue outlines, with red signifying gene upregulation and
blue signifying gene downregulation in CPTC. Node size correlates with larger absolute logFC. Edges
of the plots were determined by Functional Interaction (FI) score visualization. (B) Boxplots presenting
association of dysregulated genes’ expression with clinical variables for CPTC patients. (C) Scatterplots
correlating expression of MUC1 to that of related genes. (D) Barplot documenting number of CA/IA
genes that correlated with six clinical variables. (E) Barplot depicting number of samples that possess
the most common genomic alterations. (F) REVEALER plots illustrating genomic alteration associated
with dysregulated genes. The REVEALER analysis was conducted using CPTC samples only.
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Expressions of CA genes MUC1, FN1, and genes in the S100-family are highly correlated with
pathologic stage and pathologic TNM stages of CPTC patients (Figure 2B). While these genes have
been implicated in PTC [10,17,18], no significant correlation with clinical variables was observed in
other PTC subtypes.
We next correlated the expressions of dysregulated genes to other genes in the same pathway
to investigate possible co-expression (Spearman correlation test, p < 0.05). Notably, MUC1 exhibited
co-upregulation relationships with the IA genes B3GNT3 and PRKCD, underscoring the importance of
interaction between CA and IA pathways in CPTC (Figure 2C). MUC1 expression is also correlated with
expression of ST3GAL4. Both B3GNT3 and ST3GAL4 play a vital role in the mediation of glycosylation,
which has been linked to drug resistance and cancer progression of a host of epithelial cancers [19].
Finally, we discovered a significant number of correlations of IA gene expression to six clinical
variables in CPTC, greater than the number of correlations observed in the other two subtypes
(Figure 2D).
2.4. MUC1, FN1, and S100 family genes in CPTC correlated to alterations at tumor-associated loci
To identify copy number variations (CNVs) and mutations that are commonly associated with
the dysregulation of IA genes, the REVEALER algorithm was used [20], utilizing BROAD Firehose
genomic alteration files and gene expression data. CNV or mutation presence was considered to be
significantly associated with gene dysregulation if the CIC values output by the algorithm were greater
than 0.25 [20].
In CPTC, a majority of the genes analyzed showed a correlation between direction of dysregulation
and BRAF mutation presence (Figure 2F). Apart from the BRAF mutation, the most common CNVs
associated with gene dysregulation were located at the 1q21 locus, which has been previously identified
to be associated with cancer progression [21]. Amplifications at the 1q42 and 5p15 loci and deletions at
the 9q34 locus were also commonly associated with gene dysregulation. Studies on the 1q42 locus
have associated it with the progression of hereditary prostate cancer [22] and melanoma [23]. Lung
adenocarcinoma susceptibility has been mapped to the 5p15 locus [24]. Deletions in at the 9q34 locus are
heavily implicated in causing sporadic bladder cancer [25]. Of importance may be the commonalities
between alterations correlated to genes in the S100-family. These genes are commonly correlated with
1q21 and 1q42 amplifications, which are also the most frequent genomic alterations in CPTC aside from
BRAF mutation (Figure 2E). Interestingly, no occurrences of the BRAF mutation occurred alongside a
TERT promoter mutation, suggesting a relative rarity of this mutation in comparison to its frequency
in more aggressive thyroid cancers.
2.5. APLN, IL16, and CA/IA pathways define the FVPTC dysregulation landscape
We discovered that in contrast to genes in CPTC, dysregulated genes in FVPTC do not cluster
functionally in relation to p53 effectors or the AP-1 transcription factor network. Instead, the CA
pathways of MAPK signaling and TNF signaling as well as the IA pathways of T-cell/B-cell signaling
and Jak-STAT signaling are most prominently dysregulated in FVPTC (Figure 3A). Furthermore,
the expressions of MUC1, FN1, and S100-family genes do not correlate with the clinical variables of
FVPTC patients. Instead, the CA/IA gene APLN and IA gene IL16 associated strongly with pathologic
stage, pathologic T stage, and pathologic M stage (Figure 3B,C). IL16 is a cytokine that recruits
CD4+ immune cells, and its downregulation in FVPTC can suggest immunosuppression in the tumor
microenvironment. We also found that even though less IA gene expression correlation to clinical
variables can be found in FVPTC than in CPTC, more genes associated with metastasis in FVPTC,
which could be a result of immunosuppression at metastasis sites by FVPTC cells (Figure 3D).
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Figure 3. Pathways and genes characterizing the FVPTC dysregulation landscape. (A) ReactomeFIViz
functional clustering analysis for dysregulated genes in FVPTC vs normal samples. (B) Boxplots
presenting association of IL16 expression with clinical variables for FVPTC patients. (C) Boxplots
presenting association of APLN expression with clinical variables for FVPTC patients. (D) Barplot
documenting number of CA/IA genes that correlated with six clinical variables in FVPTC. (E) REVEALER
plots illustrating genomic alteration associated with dysregulated genes in FVPTC. (F) Barplot depicting
number of samples that possess the most common genomic alterations.
No correlation to genomic alterations was observed for APLN or IL16, but some upregulated
CA genes with no correlation to clinical variables exhibited correlations for REVEALER (Figure 3E).
This may suggest that genomic alterations play a less important role in FVPTC phenotype. FVPTC
samples also exhibit less commonality in genomic alterations than CPTC samples. Over 70% of FVPTC
samples have the BRAF mutation. The most common mutations besides BRAF were MUC, MXRA5,
and RAS mutations, although very few samples possess them (Figure 3F). The most common copy
number variations were amplifications at the 13q14, 13q34, and 9q34 loci and deletions at the 15q25
locus. The 13q14 deletion has previously been implicated in a possible epigenetic tumor-suppressor
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mechanism [26], while multiple deletions at the 13q34 locus have been implicated in head and neck
squamous cell carcinoma [27]. Alterations at the 15q25 locus are related to an increased risk for lung
cancer development [28].
2.6. RAET-Family Genes and Antigen Presentation Pathways Define the TCPTC Dysregulation Landscape
We found most pathways dysregulated in TCPTC, including TNF signaling, RXR/RAR pathways,
and chemokine signaling, to be similar to those found in the two other PTC subtypes (Figure 4A).
However, the IA pathways of FCGR dependent phagocytosis and antigen processing and presentation
are uniquely dysregulated in TCPTC. The FCGR-related genes are mostly downregulated and include
key B-cell and antibody production-related genes, while antigen processing and presentation genes are
mostly upregulated (Figure 4A). Because antibodies are produced against antigens, the dysregulation
between the two pathways may be interrelated.
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Figure 4. Pathways and genes characterizing the TCPTC dysregulation landscape. (A) ReactomeFIViz
functional clustering analysis for dysregulated genes in TCPTC vs normal samples. (B) Boxplots
presenting association of RAET1E and RAEIG expression with clinical variables.
While TCPTC exhibited the largest number of dysregulated CA and IA genes, only the expressions
of RAET1E and RAET1G correlated with clinical variables—specifically pathologic stage (Figure 4B).
The retinoic acid early transcript (RAET) proteins are stress-induced ligands for the immune cell
activating receptor NKG2D [29]. While the RAET ligands can signal immune recognition of cancer cells,
it is likely that immunosuppression within the microenvironment prevents effective RAET signaling
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in TCPTC, and the upregulation of NKG2D ligands have been linked to poor prognoses in other
cancers [30,31].
The TCPTC group could not be used to produce conclusive REVEALER results due to the low
number of patients used. Therefore, the TCPTC group was excluded from this portion of the analysis.
2.7. Differentially expressed genes between PTC subtypes exhibit strong immune association
Besides comparing PTC samples to normal samples, we also performed differential expression
analysis between the different variants of PTC and discovered a panel of genes strongly upregulated in
TCPTC compared to FVPTC (Figure 5A). This gene panel consists of IA genes CXCL17, CCL22, CD1A,
LGALS3, and ITGA3, as well as the CA genes ITGA3 and MUC1. Two genes that are both IA and CA,
BCL2 and ANGPTL1, are more highly expressed in FVPTC than TCPTC. A comparison of CPTC to
FVPTC reveals that CD1A, CCL22, CXCL17, MUC1, LGALS3, and ITGA3 are more highly expressed in
CPTC, but other genes differentially expressed between FVPTC and TCPTC, namely BCL2, ANGPTL1,
and CRABP2, are not different between CPTC and FVPTC. Finally, a comparison of CPTC to TCPTC
reveals that CXCL17 and CD1A are both upregulated in TCPTC, but no other genes from the initial
panel were significantly different in expression. Our results are consistent with the findings above,
where it was found that the dysregulation landscape of TCPTC is most different from that of FVPTC
and relatively similar to that of CPTC.
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Figure 5. Analysis of gene expression differences between PTC subtypes. (A) Heat a is alizing the
differential expression of a panel of important CA/IA genes after comparing the thre PTC subtypes
again t each other. (B) Scat er plot of ANGPTL1 expression vs. expre sion of related genes in CPTC
samples. (C) Scatter plot of ITGA3 expression vs. expression of related genes in CPTC samples. (D)
Scatter plot of LGALS3 expression vs. expression of related genes in FVPTC samples. (E) Scatter plot of
CXCL17 expression vs. NF1 expression in TCPTC samples.
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We plotted the expressions of these genes against the expressions of genes within the same
pathways and presented the highest correlations (Figure 5B–E). We found that the genes exhibited
strong correlations with other CA and IA genes. ANGPTL1 expression is associated with the expressions
of CA genes HLF, TCF4, FOXJ1, and FOXQ1 as well as expression of IA gene STAT6 in CPTC (Figure 5B).
Interestingly, the expression of ITGA3 is associated with downregulation of the oncogene VEGFA in
CTPC, suggesting that the VEGF pathway may not be involved in conferring the aggressive phenotypes
of CTPC and TCPTC (Figure 5C). VEGF pathways are also not enriched by functional gene clustering
(Figure 2A). In FVPTC samples, LGALS3, an IA gene, is strongly associated with genes associated with
blood cancers (RUNX1, BCL2L1, CBFB, and TNFRSF1A), suggesting a strong immune association in
LGALS3 activity (Figure 5D). Finally, in TCPTC samples, CXCL17 expression is inversely associated
with that of NF1, a gene that downregulates the RAS oncogene (Figure 5E).
2.8. miRNA-mediated silencing of FN1 in CPTC and ITGA3 in FVPTC
Gene set enrichment analysis (GSEA) was used to identify microRNAs (miRNAs) that silence IA
genes by identifying when upregulation of miRNAs corresponded with downregulation of CA and
IA genes.
For the CPTC subtype analyses, seven genes (ANGPTL1, ART4, BCL2, FGFR2, PRKCQ, RPS6KA5,
and TG) yielded plots that suggested potential miRNA silencing (Figure 6A). Notably, the differences
in dysregulation of TG between subtypes coincide with patterns revealed by GSEA. In previous studies,
a connection has been established between the expression of TG and FN1, in which trans-acting or
protein-protein interactions affect the development of thyroid cancer [32]. Differential expression
analysis found that FN1 was upregulated more than 10-fold in CPTC but was upregulated only six-fold
in FVPTC when compared to normal samples. The CPTC vs FVPTC differential expression analysis
validates this difference, with FN1 having logFC = 2.838 (Table S2). Additionally, FN1 is commonly
upregulated in aggressive forms of thyroid cancer [18]. Combining this information suggests a
mechanism involving both TG and FN1. Specifically, TG may regulate the expression of FN1, but is
unable to do so when acted upon by miRNAs. Therefore, the upregulation of FN1 via TG silencing
may be indicative of a disease pathway unique to CPTC.
For the FVPTC subtype, GSEA for ATIC, ITGA3, and TRIM47 suggested potential gene silencing
by miRNAs (Figure 6B). ITGA3, a member of the integrin alpha chain family of proteins that is normally
highly expressed in thyroid tissue, is downregulated in FVPTC in comparison to its expression in
other subtypes. miRNA silencing may be key to the suppression of ITGA in FVPTC. miRNAs have
been shown to silence ITGA3 expression, and in turn inhibit cancer development, in head and neck
squamous cell carcinoma [33].
For the TCPTC subtypes, there were no GSEA plots that yielded the characteristic trend that
indicates the desired correlation of low gene expression with high miRNA expression. Based on these
results, miRNAs seemingly do not have a significant effect on gene expression in TCPTC patients.
miRNAs that likely target more than one dysregulated genes were visualized. We found that a
large number of multi-target miRNAs are present in CPTC (Figure 6C), while much fewer are present
in TCPTC (Figure 6D). Interestingly, many multi-target miRNAs are located in chromosome X.
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2.9. Validation of RNA-sequencing data supports a d PTC dysregulation patterns
We utilized sequencing data fro oo et l. li ate the gene expression dysregulation we
found in CPTC and FVPTC through T . e ere not able to include TCPTC seque cing
data in the validation step due to lack of cing dataset. From analy is of the validation
coh rts, we found that IA and CA genes identified in our previous analyses to be dysregulated in CPTC
and FVPTC subtypes were almost all significantly dysregulated in the same direction in the validation
cohorts (Figure 7A–D). For a few genes—specifically ITGA3, IL16, and S100A10—the dysregulation
is significant statistically, but the fold change did not pass the threshold of significance (<−2 or >2
folds, Figure 7A,B). In addition to comparing cancer samples against normal samples, we have also
compared CPTC samples to FVPTC samples and obtained similar dysregulation trends for clinically
relevant IA and CA genes in both the TCGA and the validation patient cohorts (Figure 7E).
We summarize the most significant and clinically relevant dysregulations we uncovered in each
subtype of PTC in Figure 7F.
Cancers 2019, 11, 1179 12 of 18
Cancers 2019, 11, x 12 of 18 
 
 
Figure 7: Validation of CPTC and FVPTC CA and IA gene dysregulation. Volcano plots for (A) the 
CPTC vs normal comparison and (B) the FVPTC vs normal comparison using the validation RNA-
seq data. Genes of interest are indicated with red labels. Heatmaps comparing the landscapes of 
significantly dysregulated CA and IA genes between the validation cohort and TCGA cohort for (C) 
the CPTC vs normal comparison, (D) the FVPTC vs normal comparison, and (E) the CPTC vs. FVPTC. 
(F) Summary of most important findings. Arrows indicate possible interactions suggested by analysis 
and previous studies, red boxes indicate upregulation, and blue boxes represent downregulation. 
3. Discussion 
PTC is the only cancer with an increase in incidence for all ethnicities. Furthermore, there is an 
increased rate of diagnosis at late stages of PTC development. Although significant progress has been 
made towards characterizing the landscape of PTC, there is little information distinguishing 
pathogenesis of different PTC subtypes. Additionally, little success has been achieved in treating 
patients who have more aggressive forms of PTC such as TCPTC, especially if patient tumors lack 
the BRAF mutation [19]. Thus, it is imperative that key distinguishing features be identified for PTC 
subtypes in order to elucidate mechanisms that cause altered prognosis and that may serve as targets 
for immunotherapy. 
We profiled CA and IA pathways that are similar or different in PTC subtypes on the scales of 
individual genes, functional gene clusters, genes associated with genomic alterations, and genes 
associated with miRNA regulation. Through this multi-scale data, we propose that while CA and IA 
dysregulations are present in all subtypes, the CA pathways may be main drivers of CPTC’s 
phenotype, while IA pathways may be main divers of TCPTC’s phenotype. FVPTC may be driven 
Figure 7. Validation of CPTC and FVPTC CA and IA gene dysregulation. Volcano plots for (A)
the CPTC vs normal comparison and (B) the FVPTC vs normal comparison using the validation
RNA-seq data. Genes of interest are indicated with red labels. Heatmaps comparing the landscapes of
significantly dysregulated CA and IA genes between the validation cohort and TCGA cohort for (C)
the CPTC vs normal comparison, (D) the FVPTC vs normal comparison, and (E) the CPTC vs. FVPTC.
(F) Summary of most important findings. Arrows indicate possible interactions suggested by analysis
and previous studies, red boxes indicate upregulation, and blue boxes represent downregulation.
3. Discussion
PTC is the only cancer with an increase in incidence for all ethnicities. Furthermore, there is
an increased rate of diagnosis at lat stages of PTC development. Although sig ificant progress has
been made towards cha acterizing the landscape of PTC, there is little information distinguishing
pathogenesis of different PTC subtypes. Additionally, little success has been achieved in treating
patients who have more aggressive forms of PTC such as TCPTC, especially if patient tumors lack
the BRAF mutation [19]. Thus, it is imperative that key distinguishing features be identified for PTC
subtypes in order to elucidate mechanisms that cause altered prognosis and that may serve as targets
for immunotherapy.
We profiled CA and IA pathways that are similar or different in PTC subtypes on the scales
of in ividual ge es, functio al gene clusters, genes associated with genomic alterations, and genes
associated with miRN regulation. Through th s multi-scale data, we propose that whil CA and IA
dysregulations are present in all subtypes, the CA pathways may be main drivers of CPTC’s phenotype,
while IA pathways may be main divers of TCPTC’s phenotype. FVPTC may be driven by both CA
and IA dysregulations. In CPTC, CA genes (FN1, S100-family members, and MUC1) account for most
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of the genes with both clinical variable associations and correlation with genomic alteration events,
which are drivers of carcinogenesis. Furthermore, the largest functional pathways dysregulated are
cancer-related in CPTC. In contrast, large fractions of dysregulated genes are part of IA functional
pathways in TCPTC and FVPTC. The upregulation of several IA genes differentiates TCPTC from the
other subtypes, and only the dysregulation of RAET-family genes, central to immune-mediated cell
killing, correlated with clinical prognosis in TCPTC. Lastly, a large fraction of dysregulated genes in
TCPTC are related to antigen processing and antibody production, according to functional annotations.
Commonly altered loci were identified using the REVEALER algorithm for each subtype.
In general, the outputs indicated that CPTC was commonly implicated with alterations at the 1q21,
1q42, 5p15, and 9q34 loci. FVPTC also had increased CNVs at the 9q34 loci, as well as at the 13q14 and
13q34 loci. These loci have been implicated in the progression of other metastatic cancers. Specifically,
the 1q21 locus has been correlated with cancer progression along with MUC1 upregulation [21], further
contributing to the proposed role MUC1 has in aggressive PTC phenotype. The BRAF mutation, as well
as alterations at the 1q42 and 1q21 loci, corresponded with the dysregulation of S100 genes in CPTC.
Additionally, FN1 upregulation corresponded with high BRAF and 1q21 alteration frequency. These
relationships build on the potential significance of these genes in CPTC pathogenesis.
Silencing of IA gene expression mediated by microRNAs was identified using GSEA. In the CPTC
group, TG was identified as a promising target of miRNA silencing, with such activity correlating
more to the downregulation of TG in CPTC in comparison to the other PTC subtypes. TG silencing
could also be related to the corresponding dysregulation of FN1. Specifically, downregulation of TG
via miRNAs coincides with a comparatively lower expression of FN1, which is commonly upregulated
in aggressive forms of thyroid cancer. This may indicate a transcriptomic feature that causes CPTC
to be less aggressive than TCPTC. Additionally, MUC1, which is involved in TGF-beta signaling
from ReactomeFiViz annotations, may also be implicated in this pathway, as FN1 is inducible by
TGF-beta [12]. The downregulation of MUC1 in CPTC compared to TCPTC and subsequent potential
inactivity of TGF-beta receptor pathways may induce the altered regulation of FN1 and TG. Considering
that MUC1 upregulation and BRAF mutation presence correlate in thyroid cancer [17], our proposed
mechanism provides a pathway for the BRAF mutation to drive PTC pathogenesis and progression.
In conclusion, each subtype of PTC possesses a unique dysregulation landscape implicating CA
and IA pathways, with CA pathways being more dysregulated in CPTC and IA pathways being
more dysregulated in TCPTC, relative to each other. Experiments controlling for CA or IA pathways’
dysregulation in each subtype will be needed to elucidate the importance of CA and IA pathways in
contributing to the cancer’s phenotype, in order to inform whether tumor-intrinsic pathways or immune
pathways should be targeted for prevention of metastasis and elimination of aggressive phenotypes.
4. Materials and Methods
4.1. The Cancer Genome Atlas (TCGA) RNA-sequencing datasets and cohort designation
Level 3-normalized mRNA expression read counts for tumor samples from 345 CPTC patients, 101
FVPTC patients, and 35 TCPTC patients along with the patients’ clinical data were downloaded from
TCGA [35] on 2 February, 2018. To create a normal group to compare to the cancer groups, mRNA read
counts for adjacent solid tissue samples of 58 PTC patients were also downloaded. Patients from TCGA
study were followed until their time of death or for the maximum duration of the study—which was
4684 days. Data on patient disease progression, drug administration, and vital status recorded over
this period was used in later analysis. Patient cohorts were created from downloaded data in order to
compare PTC subtypes to each other and to normal tissue samples. These cohorts consisted of CPTC
vs Normal, FVPTC vs Normal, TCPTC vs Normal, CPTC vs FVPTC, CPTC vs TCPTC, and FVPTC
vs TCPTC. The former three cohorts were used to identify genomic and transcriptomic differences
between PTC subtypes and normal controls while the latter three cohorts were used to find differences
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in gene expression levels and clinical variable correlation between PTC subtypes. Volcano plots were
created using edgeR and inputting FDR and logFC values from the differential analysis.
4.2. Differential expression analysis to identify dysregulated immune-associated genes
Using edgeR v3.5 [36], mRNA read count inputs were filtered, resulting in the removal of lowly
expressed mRNAs (counts-per-million <1 when comparing samples from the larger group to those of
the smaller group in a cohort) from the analysis. Trimmed mean of M-values (TMM) were normalized
and pairs of mRNAs were designated to identify those that were significantly differentially expressed
when comparing one cohort to another. mRNAs considered to be significantly dysregulated were
those with fold change >2 or <−2 and false discovery rate (FDR) <0.05, output by the edgeR analysis.
After filtering for dysregulated genes, potential candidates were retained if they were considered to
be immune associated. Genes are determined to have immune association if they are involved in
adaptive or innate immune processes or in tumor antigen production. We created a list of all immune
associated genes from ImmPort [37], which lists all genes involved in adaptive or innate immune
processes, the InnateDB [38], which lists genes associated with innate immunity, and the TANTIGEN
database [39], which list CA genes.
4.3. Functional Clustering Via ReactomeFIViz
The Cytoscape software was used in tandem with the ReactomeFIViz plugin to create clusters of
gene nodes, implying similarity of function between nodes of similar modules. Fold change data was
used to adjust node details such as size and outline. Linked genes, as depicted in Figure 1D, were
taken from the program’s database by inputting a list of the IA genes of interest. Significant functions
of modules given by the clustering software were determined by FDR <0.05.
4.4. Comparing gene expression to clinical variables
Clinical significance of immune-associated genes was determined by employing the Kruskal-Wallis
test. Gene expression values were correlated with variables including pathologic stage, pathologic TMN
stage, residual tumor, histologic type, lymphocyte infiltration, monocyte infiltration, and neutrophil
invasion. In analyzing the pathologic TMN stages as individual variables, stages such as T1a and
T1b were grouped together as stage T1. Because mortality rates of THCA are generally low, patients’
MAICS scores were used to correlate immune-associated gene expression with prognosis with patients
being assigned to one of four bins designated by their scores, with higher scores corresponding with
lower survival expectancy and advanced prognosis.
4.5. Correlating gene expression with genomic alterations
CNV and mutation data was obtained from annotation files generated by the BROAD Institute
GDAC Firehose on March 31, 2018. The surface-level trends of mutation presence were analyzed by
calculating the percentage of patients with each mutation, indicated by a binary value per mutation.
The GDAC files were compiled into input files for the REVEALER (repeated evaluation of variables
conditional entropy and redundancy) algorithm, which identifies sets of specific CNVs and mutations
that are most likely implicated in changes to the target expression profile. The target profile was
identified as the expression of a single immune-associated gene. The REVEALER algorithm runs
in multiple iterations in order to identify the most prominent genomic alterations. For our study,
we set the maximum number of iterations to three. The algorithm also allows for the use of a seed,
or a particular mutation of CNV gain or loss event that may account for target activity. However,
because we did not know the individual genetic alterations that were responsible for each IA genes’
dysregulation, the seed was set to null. Significant association between genomic alteration and gene
expression was determined by conditional information coefficient (CIC) >0.25 and p-value < 0.05.
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4.6. Association of gene expression with microRNA silencing
To determine possible silencing of immune-associated gene by microRNAs, a list of differentially
expressed microRNAs was created in a similar fashion to the compilation of dysregulated genes
described previously, instead using miRNA read count files from TCGA. Input files for the Gene Set
Enrichment Analysis (GSEA) were created, detailing the miRNAs that act on each IA gene, miRNA read
counts, and mRNA read counts. The miRNAs that act on each gene were determined by consulting
the TargetScan database [40], which predicts miRNA activity based on conserved sites on DNA and
corresponding miRNA. The GSEA program determines whether the miRNAs that act on a single gene
show significant differences in expression when coupled with dysregulation of the gene. The program
assigns enrichment scores to each miRNA based on the expression of the target gene, assigning high
enrichment scores when high miRNA expression correlated with high gene expression. In addition,
the miRNAs are ranked based on their level of dysregulation, resulting in a final list that ranks miRNAs
from highest to lowest dysregulation. A final enrichment plot is created that compares miRNAs’
list ranks to their enrichment scores. Because miRNAs silence gene expression, high list ranks must
correlate to low enrichment scores in order for a significant relationship to be identified. miRNAs are
determined to influence gene expression if the nominal p-value for a negative correlation between list
rank and enrichment score is <0.05. Circos plots were generated from GSEA results to link analyzed
miRNAs to the genes that they may regulate. The plots were created by inputting miRNA and IA gene
genome location data into the Circos software [41].
4.7. Determination of co-Expression between dysregulated genes and related genes
To determine the effect of IA or CA gene dysregulation on other genes that share common
pathways with the CA/IA genes, lists of genes in the same pathways as selected CA/IA genes were
obtained from the Pathway Commons [42]. Lists were filtered for interactions in which CA/IA genes
acted on or were acted on by other genes. CPM data for the genes from the remaining relationships
was compared to that of the CA/IA genes using edgeR. Possible co-expression was indicated by plots
with p-value < 0.05.
4.8. Validation of TCGA RNA-sequencing datasets
Using RNA-sequencing data performed on CPTC, FVPTC and adjacent normal thyroid tissue in
Yoo et al. [34], differential expression analysis, as described above, was completed in order to validate
results obtained using TCGA datasets. Datasets for 77 CPTC samples, 48 FVPTC samples, and 81
matched adjacent normal samples were available. The STAR RNA-seq aligner [43] was used to convert
the RNA-sequencing data into a counts format.
5. Conclusions
We conclude that several immune and cancer-associated genes and pathways define an
RNA-expression dysregulation landscape that is unique to each individual PTC variant. Specifically,
MUC1, S100-family genes, FN1, and several CA pathways characterize CTPC; APLN, IL16, MAPK
signaling, and several IA pathways characterize FVTPC; and RAET-family genes and the antigen
presentation pathway characterize TCPTC. We also implicate miRNAs in the downregulation of certain
genes and present a possible mechanism for miRNA-mediated suppression of TG.
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